CC-885 NEW
| Price | $51 | $122 | $172 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: CC-885 | CAS No.: 1010100-07-8 |
| Purity: 99.83% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | CC-885 |
| Description | CC-885 is a modulator of cereblon (CRBN). It has potent anti-tumour activity. |
| In vitro | CC-885 exhibits stronger antiproliferative effects than Lenalidomide and Pomalidomide across various cell types, including acute myeloblastic leukemia (AML) cell lines, THLE-2 human liver epithelial cells, and human peripheral blood mononuclear cells (PBMC), with IC50 values ranging from 10×-6-1 μM. The compound's efficacy was also assessed in 293T HEK cells engineered to express variants of GSPT1 that are either sensitive or resistant to CC-885. The study further explores the mechanism behind CC-885's cytotoxicity, particularly its dependency on cereblon-mediated degradation of GSPT1. By utilizing a GSPT1 mutant which maintains its functionality but lacks the cereblon binding affected by CC-885, the research distinguishes GSPT1's role from other potential targets. Notably, cells overexpressing the CC-885-resistant GSPT1 variant (GSPT1Δ(1–138)/(G575N)) were completely resistant to the compound's inhibitory effects on cell proliferation. In contrast, overexpressing a CC-885-sensitive variant (GSPT1Δ(1-138)) provided only partial protection against these effects, indicating the critical role of GSPT1 degradation in CC-885's mechanism of action. Similar outcomes were observed in AML cell lines[1]. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 67.5 mg/mL (153.1 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 2.5 mg/mL (5.67 mM), Sonication is recommended. |
| Keywords | Ligands for E3 Ligase | LigandforE3Ligase | Ligand for E3 Ligase | Inhibitor | inhibit | E3 ligase-recruiting Moiety | CRBN | cereblon | CC-885 | CC885 | CC 885 |
| Inhibitors Related | Lenalidomide-Br | Acetyl-cyclosporin A aldehyde | PT-179 | (S)-Thalidomide | BI-3802 | Thalidomide | (S,R,S)-AHPC | Pomalidomide | Amino-PEG1-C2-acid | Lenalidomide | (S,R,S)-AHPC hydrochloride | 5-Aminothalidomide |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:917471-30-8
-
-
CAS:71-33-0
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY